The estimated Net Worth of Growth Fund Limited Partner... is at least $31.3 Million dollars as of 9 June 2021. Growth Partner owns over 1,000,000 units of Seer stock worth over $1,305,647 and over the last 4 years Growth sold SEER stock worth over $30,000,000.
Sign up
Growth Partner SEER stock SEC Form 4 insiders trading
Growth has made over 2 trades of the Seer stock since 2020, according to the Form 4 filled with the SEC. Most recently Growth sold 1,000,000 units of SEER stock worth $30,000,000 on 9 June 2021.
The largest trade Growth's ever made was selling 1,000,000 units of Seer stock on 9 June 2021 worth over $30,000,000. On average, Growth trades about 629,824 units every 61 days since 2020. As of 9 June 2021 Growth still owns at least 810,961 units of Seer stock.
You can see the complete history of Growth Partner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Seer
Over the last 7 years, insiders at Seer have traded over $150,878,393 worth of Seer stock and bought 1,798,420 units worth $33,507,980 . The most active insiders traders include Omid Farokhzad, Terrance Mcguire und Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of $227,813. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth $21,554.
What does Seer do?
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
What does Seer's logo look like?
Complete history of Growth Partner stock trades at Ayala Pharmaceuticals und Seer
Seer executives and stock owners
Seer executives and other stock owners filed with the SEC include:
-
Dr. Omid C. Farokhzad M.D., Ph.D.,
Founder, CEO & Chair of the Board of Directors -
Dr. Omid C. Farokhzad Ph.D., M.D.,
CEO & Chair of the Board of Directors -
Omead Ostadan,
Part Time Pres, COO & Director -
David R. Horn,
Exec. VP & Chief Financial Officer -
Martin Goldberg Ph.D.,
Sr. VP of Devel. -
Elona Kogan Esq., J.D.,
Gen. Counsel & Sec. -
Marissa Dixon,
VP & Chief People Officer -
Jennifer Maggio,
VP & Corp. Controller -
Dr. Serafim Batzoglou,
VP & Chief of Computation -
Shashanka Muppaneni,
VP of Corp. Devel. -
Karen Possemato,
VP of Corp. Marketing & Communications -
Elona Kogan J.D., Esq.,
Gen. Counsel & Sec. -
Dr. Philip Ma Ph.D.,
Founder & Strategic Advisor -
Joe Laws,
Chief Technology Officer and Co-Founder -
David Hallal,
-
Rachel E. Haurwitz,
-
Dipchand Nishar,
-
Mostafa Ronaghi,
Director -
David B Singer,
Director -
Public Equities, L.P.Invus ...,
-
Omead Ostadan,
President & COO -
David R. Horn,
PRESIDENT & CFO -
Growth Fund Limited Partner...,
-
Capital Ventures, Llc Maver...,
-
Cathy Friedman,
Director -
Terrance Mcguire,
-
Capital Ventures, Llc Maver...,
-
Robert Langer,
-
Scott D Thomas,
Chief Commercial Officer -
Public Equities, L.P.Artal ...,
-
Meeta Gulyani,
-
Omid Farokhzad,
CEO AND CHAIR -
Elona Kogan,
CHIEF LEGAL OFFICER -
Nicolas H Phd Roelofs,